Approximately 4% of SMA patients are not genetically linked to 5q13 and, although these cases belong to the less severe SMA types 3 and 4 or in many cases have a somewhat different phenotype, there is an urgent need for developing SMN-independent therapies to address motor neuron degeneration in these patients. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.